Judith Hasko

Judith Hasko is the Chair of the Transactional Department and Co-Chair of WilmerHale’s Life Sciences Practice. She provides counsel to life sciences companies and their investors on strategic, intellectual property and technology-based commercial transactions. Companies in the biotechnology, pharmaceutical, medical device and diagnostic product sectors, along with their investors, depend on Ms. Hasko for guidance and execution of licensing, corporate partnerships, joint ventures, co-promotion arrangements, manufacturing and distribution agreements, asset purchases and royalty stream transactions.

Widely recognized for her market-leading transactional work, Ms. Hasko brings complementary business and scientific perspectives to her legal representations. She is ranked in Band 1 by Chambers USA in Life Sciences: Corporate/Commercial in both California and nationwide, and is consistently recognized by The Legal 500 United States, IAM Patent and LMG Life Sciences. Clients rely on her for her business acumen and knowledge of the life sciences industry, with one telling Chambers USA she “is an insanely talented attorney and a force of nature in this space."

Prior to joining the firm, Ms. Hasko was a partner in the Silicon Valley office of another major international law firm, where she served as vice chair of their Healthcare & Life Sciences Practice.

Bar Admissions:

California

Admissions:

US Patent and Trademark Office

Over the course of her career, Ms. Hasko has represented clients on a variety of significant transactions. Some of her experience includes advising:

Sonoma Biotherapeutics in its collaboration with Regeneron Pharmaceuticals to apply their scientific and clinical expertise and respective technology platforms to the discovery, development, and commercialization of novel regulatory T cell therapies for autoimmune diseases in a deal valued up to $120 million. The parties will focus on treatments for ulcerative colitis, Crohn’s disease and two other undisclosed indications, subject to an option for a fifth indication, and will equally co-fund research and development for all potential products and share equally any future commercial expenses and profits.

Daiichi Sankyo in a $6.9 billion oncology collaboration with AstraZeneca in 2019.

Novan in an exclusive license agreement with Sato Pharmaceutical to grant exclusive rights to develop and commercialize in Japan Novan's topical nitric oxide-releasing product candidate SB204, which was named a 2017 LMG Life Sciences Impact Case of the Year.

Juno Therapeutics in its landmark investment and collaboration with Celgene to develop CAR-T and TCR products, valued at more than $1 billion. The transaction earned the Thomson Reuters Allicense 2015 Breakthrough Award and LMG Life Sciences Collaboration Impact Deal of the Year for 2015.

OncoMed in a collaboration with Celgene, valued at more than $3.3 billion, which received the In Vivo Alliance of the Year Award for 2013.

Prothena Biosciences and Neotope Biosciences in a license, development, and commercialization agreement with F. Hoffmann-La Roche and Hoffmann-La Roche, to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease.

OncoMed in its collaboration with Bayer Schering Pharma, valued at more than $1.4 billion, which received the BayBio Pantheon 2010 DiNA Award.

University of Wisconsin Law School

JD

1994

University of Sussex

MPhil

1988

Vassar College

BA

1986